Results 141 to 150 of about 137,213 (265)

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

Protective role of Boerhavia diffusa root extract in methotrexate-induced renal injury: evidence from oxidative stress, molecular, and immunohistochemical markers. [PDF]

BMC Complement Med Ther
Dinesh Kumar R, Lakshmanan G, Kalpana R, Senthilkumar S, Rajan M, Saraswathi I, Saikarthik J.   +6 more
europepmc   +1 more source

Precision Chemistry for Protein Lysine Modification

Chemistry – A European Journal, EarlyView.
Selective modification of lysine residues is challenging due to their similar intrinsic reactivity. Inspired by enzymatic recognition, ligand‐guided electrophiles enable site‐selective labeling and functionalization, while ligand‐guided catalyses achieve regioselective installation of bio‐relevant post‐translational modifications.
Mayu Onoda, Motomu Kanai
wiley   +1 more source

Effects of Chemotherapeutic Agents (5-Fluorouracil, Cisplatin and Methotrexate) on Cell Adhesion Molecules and Oxidative Damage Markers in Rat Kidney Tissue. [PDF]

Basic Clin Pharmacol Toxicol
Ozyapici SE, Dundar MO, Atakisi O.
europepmc   +1 more source

Control of Gemcitabine Activity With Blue and Red Light

Chemistry – A European Journal, EarlyView.
Treating cancer with chemotherapy is generally associated with many side effects, which can be addressed by selectively releasing the desired drugs with visible light. Sixteen new blue light‐activatable cytostatics were introduced, with the gemcitabine derivative exhibiting ideal properties.
Nils F. Kersten, Konstantin L. Stock, Marius Hyprath, Hannah Weisser, Timo Weinrich, Dieter Steinhilber, Alexander Heckel   +6 more
wiley   +1 more source

Avelumab Plus Methotrexate for Gestational Trophoblastic Tumors: The TROPHAMET Phase 1/2 Nonrandomized Clinical Trial.

JAMA Oncol
You B, Lotz JP, Descargues P, Joly F, De La Motte Rouge T, Lebreton C, Gladieff L, Follana P, Jamelot M, Massardier J, Hajri T, Msika A, Alves-Ferreira M, Bin S, Langlois-Jacques C, Subtil F, Roux A, Desauw C, Provansal M, Schwiertz V, Golfier F, Bolze PA.   +21 more
europepmc   +1 more source

A methotrexate dashboard: integrating MTXPK.org into the electronic health record to facilitate model-informed care for pediatric patients receiving high-dose methotrexate. [PDF]

JAMIA Open
Taylor ZL, Punt N, Jenkinson C, Vidonish B, Young J, O'Brien MM, Ramsey LB.   +6 more
europepmc   +1 more source

Methotrexate pharmacogenomics [PDF]

Annals of the Rheumatic Diseases, 2006
openaire   +2 more sources

Clinical Model‐Informed Precision Dosing Consult Service for Accelerating Personalized Medication in Pediatric Patients

Clinical Pharmacology &Therapeutics, EarlyView.
Traditional dosing strategies often rely on a “one‐size‐fits‐all” paradigm, assuming an “average” patient with typical demographic and pharmacological characteristics. In reality, this often overlooks existing between‐patient variability and can lead to suboptimal drug exposure or toxicity. This issue is especially pronounced in pediatric patients, who
Zachary L. Taylor, Takanobu Nadai, Kei Irie, Wen Rui Tan, Sanjana Parikh, Anhar Hosawi, Matthijs W. van Hoogdalem, Ronaldo Morales Junior, Sonya Tang Girdwood, Abbie D. Leino, Kana Mizuno, Alexander A. Vinks, Tomoyuki Mizuno   +12 more
wiley   +1 more source

Drug-Free Remission of VEXAS Syndrome Without Stem Cell Transplantation. [PDF]

Cureus
Warren J, Smylie C, Milne A.
europepmc   +1 more source